. Author manuscript; available in PMC: 2014 Jul 28.

Published in final edited form as: Biol Blood Marrow Transplant. 2009 Oct 14;16(2):287–291. doi: 10.1016/j.bbmt.2009.10.008

Table 1.

Demographic characteristics of EBV-monitored patients as compared to historical controls

Factors	Historical Controls	Current Cohort	P-value
Number of patients	30	34	NA
Median age (year)	55 (19–69)	56 (36–67)	.24
Median weight (kg)	85 (50–134)	80 (52–111)	.08
CMV-positive recipients	12 (40%)	24 (71%)	.02
Median infused nucleated cell dose × 10⁸/kg	0.35 (0.21–0.68)	0.35 (0.22–0.59)	.94
Median infused CD34⁺ cell dose × 10⁶/kg	0.44 (0.07–1.66)	0.38 (0.14–1.32)	.27
Median time to follow up (day)	219 (7–1056)	339 (31–765)	.59
HLA match (worst match)			<.01
6 of 6	0	1 (3%)
5 of 6	0	16 (47%)
4 of 6	30 (100%)	17 (50%)
No. of UCB recipients (%)			1.00
Single unit	1 (3%)	2 (6%)
Double unit	29 (97%)	32 (94%)
No. with malignant diagnosis at Tx (%)	28 (93%)	33 (97%)	.60
EBV subgroups	6	8	.10
Viremia	1 (3%)	6 (18%)
PTLD	5 (17%)	2 (6%)

P values for the comparison of categorical and continuous variables were performed from the Fisher’s exact test and wilcoxon singed rank test, respectively.